Advertisement

Topics

Companies Related to "Study of the Safety and Efficacy of Ruxolitinib Cream for Non-Sclerotic Chronic Cutaneous Graft-Versus-Host Disease" [Most Relevant Company Matches] RSS

21:13 EDT 26th June 2019 | BioPortfolio

Here are the most relevant search results for "Study of the Safety and Efficacy of Ruxolitinib Cream for Non-Sclerotic Chronic Cutaneous Graft-Versus-Host Disease" found in our extensive corporate database of over 50,000 company records.

Showing "Study Safety Efficacy Ruxolitinib Cream Sclerotic Chronic Cutaneous" Companies 1–25 of 2,900+

Relevant

TheraCoat

TheraCoat is a specialty pharmaceutical company founded in 2004 by uro-oncologists and biomaterial specialists. TheraCoat’s Board of Directors and Scientific Advisory Board feature renowned scientific experts in the fields of urology, pharma top executives and experienced business veterans; among them Prof. Belldegrun and Mr. Hurvitz, both TEVA Board ...


Baskin-Robbins

Named the top ice cream and frozen dessert franchise in the United States by Entrepreneur magazine's 30th annual Franchise 500® ranking, Baskin-Robbins is the world's largest chain of ice cream specialty shops. Baskin-Robbins creates and markets innovative, premium ice cream, specialty frozen desserts and beverages, providing quality and value to consumers at more than 5,800 retail shops in more...

Alkemie Ice Cream LLC

Alkemie Ice Cream LLC is based in San Mateo, CA and is devoted to creating rich, creamy, and highly nutritious frozen desserts.


Matterhorn Group

Matterhorn Group is the largest independent producer of ice cream novelties in the Western United States. MGI produces a wide variety of packaged ice cream and novelties including frozen juice, yogurt and sherbet for retail grocery and convenience and mobile vending channels as well as the food service sector including hotels, restaurants, cafeterias and hospitals. Crystal Light is a registered tr...

Shape Pharmaceuticals, Inc.

Shape Pharmaceuticals, Inc. is developing SHP-141, a novel, topical, “soft-drug” HDAC inhibitor for the treatment of patients with cutaneous T cell lymphoma (CTCL) and psoriasis. Shape has an ongoing Phase 1b clinical study in CTCL patients and has completed a Phase 1b clinical study in psoriasis patients. The development of SHP-141 is being supp...

Shamrock Farms

Shamrock Farms, the largest dairy in the Southwest, produces and distributes traditional and organic farm-fresh milk throughout the country, including at all 22,000 SUBWAY® Restaurants nationwide. In its home state of Arizona, Shamrock Farms also distributes whipping cream, sour cream, cottage cheese, ice cream and frozen novelties. Shamrock Farms, which has its own farm hosting a herd of more th...

Celtaxsys, Inc.

Celtaxsys is privately-held start-up focused on discovery and development of therapeutics to treat inflammation. The Company has identified a portfolio of immunoregulators that redirect immune cell migration and activation. Initial product candidates can ameliorate acute and chronic inflammatory disorders of cutaneous, and other, barrier epithelia.

AtheroGenics Incorporated

AtheroGenics is an emerging pharmaceutical company focused on the discovery, development and commercialization of novel drugs for the treatment of chronic inflammatory diseases, such as atherosclerosis, rheumatoid arthritis and asthma. AtheroGenics has cultivated a drug discovery and development capability directed toward rapidly creating and transporting small molecule therapeutics into the clini...

Coeur Scientific Inc.

Coeur Scientific Inc. is a contract development company committed to providing expert consultations and complete in vivo, in vitro preclinical study management in a state-of-the-art professional environment. These services produce detailed and thorough information on the efficacy and safety of new medical devices, procedures and therapeutic agents. Our primary objective is to deliver quality dat...

Biofrontera AG

Biofrontera AG is a biopharmaceutical company specializing in the development of drugs for the treatment of dermatological and inflammatory diseases. The Company has three product candidates in clinical development for four different clinical indications. The most advanced products are BF-200 ALA (Phase IIb/III) for actinic keratosis and condyloma; and BF-derm 1 (Phase II) for chronic, antihistami...

NeuroTherapeutics Pharma, Inc.

NeuroTherapeutics Pharma is a privately held life sciences company which is focused on the discovery and development of novel therapeutics for patients suffering from CNS disorders. The company is developing compounds that decrease or eliminate aberrant excitatory discharges by working through a new mechanism of action which is unlike that of any marketed ...

Bioxyne

Bioxyne Limited (ASX:BXN) is an Australian immunotherapeutics business created in April 2012 through the reverse takeover of Probiomics (ASX: PCC) by privately held Hunter Immunology. The Company’s lead therapy, HI-164OV is based on the Company’s proprietary technology that uses the application of mucosal immunology to treat common human diseases.  HI-164OV, in Phase IIb clinica...

Guildford Clinical Pharmacology

Guildford Clinical Pharmacology Ltd (GCPL) has wide experience of efficient study designs in Phases 1 & 2 and develops new surrogate markers especialy for analgesics, the CNS and gastrointestinal drugs. We can use high tech equipment and the staff to run it correctly; recent examples being: 1) Gamma cameras for colonic transit measurements in a proof of efficacy study on a morphine antagonist an...

Aranesp

Aranesp® (darbepoetin alfa) is indicated for the treatment of anemia associated with chronic renal failure (CRF), including patients on dialysis and patients not on dialysis, and for the treatment of anemia in patients with nonmyeloid malignancies where anemia is due to the effect of concomitantly administered chemotherapy.Important Product Safety InformationAranesp® is contraindicated in patien...

Quintiles Scotland

Safety PharmacologyQuintiles has safety pharmacology services to identify the potential adverse pharmacological effects of new chemical entities prior to first administration to man. Regulatory Safety Pharmacology packages Haemodynamics/ECG studies Cardiac action potential in vitro QT prolongationIon channels (e.g. HERG) Discovery SupportQuintiles pharmacologists can provide support in defining th...

Winston Pharmaceuticals, Inc.

Winston is a pharmaceutical company focused on pain control which is developing products for large pain control markets, as well as for niche markets, where there are still significant unmet needs for pain management options with improved efficacy, safety, and tolerability profiles. Winston's late stage product candidates include osteo- and rheumatoid arth...

Augmenix, Inc.

Augmenix, Inc. is a privately held company based in Waltham, Mass., focused on the development and commercialization of implantable biomaterial based solutions for improved radiotherapy safety and/or efficacy. Augmenix's first product, SpaceOAR system is an injectable tissue spacer that will decrease rectal morbidity or enable improved efficacy in prostate radiotherapy. The company was founded in ...

Graceway Pharmaceuticals, LLC

Graceway Pharmaceuticals, LLC ("Graceway"), headquartered in Bristol, TN, is a pharmaceutical company focused on acquiring, in-licensing, and developing branded prescription pharmaceutical products. Graceway has acquired or licensed products from 3M (NYSE: MMM), Pfizer (NYSE: PFE) and Gilead (NASDQ: GILD). Current prescription products marketed by Graceway...

CLINICAL RESEARCH LABORATORIES, INC

Clinical Research Laboratories, Inc. (CRL) was incorporated in 1992. Today, CRL operates as an independent contract laboratory providing a wide range of clinical safety and efficacy testing to the cosmetic and pharmaceutical industries. Located in central New Jersey, CRL is dedicated to conducting human clinical test procedures to determine the safety and efficacy of cosmetic, personal care, and O...

Endosense

Founded in Geneva in 2003, Endosense is a medical technology company focused on improving efficacy, safety and reproducibility of catheter ablation for the treatment of cardiac arrhythmias. The company has pioneered the use of contact force measurement in catheter ablation, with the development of its proprietary Touch+® sensor technology. Endosenseâ€...

Pearl Therapeutics Inc.

Pearl Therapeutics is developing combination therapies for the treatment of highly prevalent respiratory diseases, including chronic obstructive pulmonary disease (COPD) and asthma. Leveraging its proprietary particle technology, formulation expertise and unparalleled product development experience, Pearl is rapidly advancing a pipeline of products that offer patients and healthcare professionals ...

Gloucester Pharmaceuticals

Gloucester Pharmaceuticals acquires clinical-stage oncology drug candidates and advances them through regulatory approval and commercialization. The Company’s first candidate, ISTODAX® (romidepsin), a novel histone deacetylase (HDAC) inhibitor, is FDA approved for the treatment of cutaneous T-cell lymphoma (CTCL) in patients who have received at le...

TxCell

TxCell, a spin-off of Inserm (France’s National Institute for Health and Medical Research) is located in the Sophia Antipolis technology park, Nice, France. It is developing innovative personalized cell-based immunotherapies for the treatment of severe chronic inflammatory diseases with high medical need using its unique and proprietary technology platform based on the properties of autolo...

Neurowave Medical Technologies

Neurowave Medical TechnologiesTM (NMT) is a rapidly growing, privately held Chicago-based medical device company that develops and manufactures transdermal neuromodulation devices for the treatment of a wide range of acute and chronic clinical conditions. Using its patented and proprietary neuromodulation technology platform, NMT’s mission is to take ...

AcelRx Pharmaceuticals, Inc.

AcelRx Pharmaceuticals is a privately held pharmaceutical company dedicated to the development and commercialization of new therapies for the treatment of pain and other conditions where there is an unmet need for improved safety and efficacy. The company applies its proprietary dosage form and delivery technologies to enhance the safety, therapeutic benefit and commercial attractiveness of curren...


More From BioPortfolio on "Study of the Safety and Efficacy of Ruxolitinib Cream for Non-Sclerotic Chronic Cutaneous Graft-Versus-Host Disease"

Advertisement
Quick Search
Advertisement
Advertisement

 

Corporate Database Quicklinks